Adlai Nortye (ANL) Total Current Liabilities (2022 - 2025)
Adlai Nortye (ANL) reported Total Current Liabilities of $41.6 million for Q4 2025, down 8.23% year-over-year from $45.4 million in Q4 2024, and down 34.82% on a QoQ basis from $63.9 million in Q2 2025.
Adlai Nortye (ANL) has 4 years of Total Current Liabilities data on file, last reported at $41.6 million in Q4 2025.
- Quarterly Total Current Liabilities fell 8.23% year-over-year to $41.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $41.6 million (down 8.23% YoY) and the FY2025 annual result came in at $41.6 million, down 8.23% from the prior year.
- Total Current Liabilities eased to $41.6 million in Q4 2025 per ANL's latest filing, from $63.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $312.7 million in Q4 2022 and bottomed at $41.6 million in Q4 2025.
- The 4-year median for Total Current Liabilities is $52.0 million (2023), against an average of $94.6 million.
- The widest annual swing landed in 2023, when Total Current Liabilities slumped 84.11%; it then rose 17.59% in 2025.
- Tracing ANL's Total Current Liabilities over 4 years: stood at $312.7 million in 2022, then tumbled by 84.11% to $49.7 million in 2023, then dropped by 8.68% to $45.4 million in 2024, then decreased by 8.23% to $41.6 million in 2025.
- Per Business Quant, the three latest ANL Total Current Liabilities figures stand at $41.6 million (Q4 2025), $63.9 million (Q2 2025), and $45.4 million (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 5.11 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Adlai Nortye | 23,840.00 | -8.03 Mn | - | 41.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 41.63 Mn |
| Jun 30, 2025 | 63.87 Mn |
| Dec 31, 2024 | 45.36 Mn |
| Jun 30, 2024 | 54.31 Mn |
| Dec 31, 2023 | 49.67 Mn |
| Dec 31, 2022 | 312.65 Mn |